Skip to Main Content

It’s a bad run for generic drug companies at the Supreme Court.

The court on Monday denied three separate requests from generic drug makers hoping the justices would revisit lower-court decisions the industry doesn’t like.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!